Ask Our Doctors – Archive

Our Medical Directors are outstanding physicians that you will find to be very personable and compassionate, who take care to ensure that you have the most cutting-edge fertility treatments at your disposal. This is your outlet to ask your questions to the doctors.

19,771 Comments

  1. Hello Dr. Sher
    My question is regarding immunologic implantation dysfunction.
    I am 32 and my husband 38, actively TTC for 3 years and zero pregnancies.
    My GYN insisted on a laparoscopy after 1 year of TTC based on a few symptoms I had, and confirmed mild endometriosis (mostly removed at the time) and uterine polyps (all taken care) and sent me to a RE.
    We received a diagnosis of “unexplained infertility” from 2 different REs despite the confirmation of endometriosis and a few routine tests. We failed 4 IUIs and one IVF that resulted in three embryos (day 5) proven to be genetically abnormal after PGS. We recently tried IVF again and got 4 genetically normal embryos and I have my first FET scheduled for January.
    Could immunologic dysfunction be the cause for my “unexplained infertility”? Do you think it would be wise to look into it prior to the embryo transfer?
    Thank you in advance.
    Geovanna

    • More than half of women who have endometriosis harbor antiphospholipid antibodies (APA) that can compromise development of the embryo’s root system (trophoblast). In addition and far more serious, is the fact that in about one third of cases endometriosis, regardless of its severity is associated with NKa and cytotoxic uterine lymphocytes (CTL) which can seriously jeopardize implantation. This immunologic implantation dysfunction (IID) is diagnosed by testing the woman’s blood for APA, for NKa (using the K-562 target cell test or by endometrial biopsy for cytokine activity) and, for CTL (by a blood immunophenotype). Activated NK cells attack the invading trophoblast cells (developing “root system” of the embryo/early conceptus) as soon as it tries to gain attachment to the uterine wall. In most cases, this results in rejection of the embryo even before the pregnancy is diagnosed and sometimes, in a chemical pregnancy or an early miscarriage. As such, many women with endometriosis, rather than being infertile, in the strict sense of the word, often actually experience repeated undetected “mini-miscarriages”.
      Women who harbor APA’s often experience improved IVF birth rates when heparinoids (Clexane/Lovenox) are administered from the onset of ovarian stimulation with gonadotropins until the 10th week of pregnancy. NKa is treated with a combination of Intralipid (IL) and steroid therapy: Intralipid (IL) is a solution of small lipid droplets suspended in water. When administered intravenously, IL provides essential fatty acids, linoleic acid (LA), an omega-6 fatty acid, alpha-linolenic acid (ALA), an omega-3 fatty acid.IL is made up of 20% soybean oil/fatty acids (comprising linoleic acid, oleic acid, palmitic acid, linolenic acid and stearic acid) , 1.2% egg yolk phospholipids (1.2%), glycerin (2.25%) and water (76.5%).IL exerts a modulating effect on certain immune cellular mechanisms largely by down-regulating NKa.
      The therapeutic effect of IL/steroid therapy is likely due to an ability to suppress pro-inflammatory cellular (Type-1) cytokines such as interferon gamma and TNF-alpha. IL/steroids down-regulates NKa within 2-3 weeks of treatment the vast majority of women experiencing immunologic implantation dysfunction. In this regard IL is just as effective as Intravenous Gamma globulin (IVIg) but at a fraction of the cost and with a far lower incidence of side-effects. Its effect lasts for 4-9 weeks when administered in early pregnancy.
      The toxic pelvic environment caused by endometriosis, profoundly reduces natural fertilization potential. As a result normally ovulating infertile women with endometriosis and patent Fallopian tubes are much less likely to conceive naturally, or by using fertility agents alone (with or without intrauterine (IUI) insemination. The only effective way to bypass this adverse pelvic environment is through IVF. I am not suggesting here that all women who have endometriosis require IVF! Rather, I am saying that in cases where the condition is further compromised by an IID associated with NKa and/or for older women(over 35y) who have diminished ovarian reserve (DOR) where time is of the essence, it is my opinion that IVF is the treatment of choice.

      I strongly recommend that you visit https://www.drgeoffreysherivf.com. Then go to my Blog and access the “search bar”. Type in the titles of any/all of the articles listed below, one by one. “Click” and you will immediately be taken to those you select. Please also take the time to post any questions or comments with the full expectation that I will (as always) respond promptly.
      • The IVF Journey: The importance of “Planning the Trip” Before Taking the Ride”
      • Controlled Ovarian Stimulation (COS) for IVF: Selecting the ideal protocol
      • IVF: Factors Affecting Egg/Embryo “competency” during Controlled Ovarian Stimulation(COS)
      • The Fundamental Requirements For Achieving Optimal IVF Success
      • Ovarian Stimulation for IVF using GnRH Antagonists: Comparing the Agonist/Antagonist Conversion Protocol.(A/ACP) With the “Conventional” Antagonist Approach
      • Ovarian Stimulation in Women Who have Diminished Ovarian Reserve (DOR): Introducing the Agonist/Antagonist Conversion protocol
      • Anti Mullerian Hormone (AMH) Measurement to Assess Ovarian Reserve and Design the Optimal Protocol for Controlled Ovarian Stimulation (COS) in IVF.
      • The Role of Immunologic Implantation Dysfunction (IID) & Infertility (IID):PART 1-Background
      • Immunologic Implantation Dysfunction (IID) & Infertility (IID):PART 2- Making a Diagnosis
      • Immunologic Dysfunction (IID) & Infertility (IID):PART 3-Treatment
      • Thyroid autoantibodies and Immunologic Implantation Dysfunction (IID)
      • Immunologic Implantation Dysfunction: Importance of Meticulous Evaluation and Strategic Management:(Case Report
      • Intralipid and IVIG therapy: Understanding the Basis for its use in the Treatment of Immunologic Implantation Dysfunction (IID)
      • Intralipid (IL) Administration in IVF: It’s Composition; How it Works; Administration; Side-effects; Reactions and Precautions
      • Natural Killer Cell Activation (NKa) and Immunologic Implantation Dysfunction in IVF: The Controversy!

      Please call or email Julie Dahan, my patient concierge. She will guide you on how to set up an in-person or Skype consultation with me. You can reach Julie at on her cell phone or via email at any time:
      Julie Dahan
      • Email: Julied@sherivf.com
      • Phone: 702-533-2691
      ? 800-780-7437

      Geoff Sher

      I also suggest that you access the 4th edition of my book ,”In Vitro Fertilization, the ART of Making Babies”. It is available as a down-load through http://www.Amazon.com or from most bookstores and public libraries.

  2. I was wondering which one is better frozen or fresh? I have epilepsy and I am triggered by hormones which my IVF doctor doesn’t seem worried about at all but I am very worried, I know my body. Anyway, frozen she will only implant one so it’s not like we have a number increase that can help. Not sure what to do here.

    • Until less than a decade ago, most women undergoing IVF would have their embryos transferred to the uterus in the same cycle that the egg retrieval was performed (“Fresh” Embryo Transfer). This was because embryo cryopreservation (freezing) was a hazardous undertaking. In fact it resulted in about 30% not surviving the freezing process and those that did, having about one half the potential of “fresh embryos to implant and propagate a viable pregnancy. The main reason for the high attrition rate associated with embryo cryopreservation is that the “conventional” freezing” process that was done slowly and this resulted in ice forming within the embryo’s cells, damaging or destroying them. The recent introduction of an ultra-rapid cryopreservation process known as vitrification freezes the embryos so rapidly as to avoid ice crystals from developing. As a result, >90% survive the freeze/thaw process in as good a condition as they were prior to being frozen and thus without being compromised in their ability to propagate a viable pregnancy.
      Recently, there have been several articles that have appeared in the literature suggest that an altered hormonal environment may be the reason for this effect. There have also been reports showing that when singletons (pregnancy with one baby) conceived naturally are compared to singletons conceived through a “fresh” embryo transfers they tend to have a greater chance of low birth weight/prematurity. This difference was not observed in babies born following FET. Hence, there is a suspicion that the altered hormonal environment during the fresh cycle may be the causative factor.
      Available evidence suggests that FET (of pre-vitrified blastocysts) is at least as successful as is the transfer of “fresh” embryos and might even have the edge. The reason for this is certainly unlikely to have anything to do with the freezing process itself. The reason likely has to do with being able to better able to prepare the uterus optimally for embryo implantation by using targeted hormone replacement therapy that when a “fresh” transfer is performed immediately following ovarian stimulation with fertility drugs.
      There are additional factors other than method used for embryo cryopreservation that influence outcome following FET. These include
      •An emerging trend towards selective transferring only advanced (day 5-6) embryos (blastocysts).
      • (PGS) to allow for the selective transfer of genetic competent (euploid) embryos
      •Addressing underlying causes of implantation dysfunction (anatomical and immunologic uterine factors) and
      • Exclusive use of ultrasound guidance for delivery of embryos transferred to the uterus.

      Against this background, the use of FET has several decided advantages:
      •The ability to cryostore surplus embryos left over after fresh embryo transfer
      •The ability to safely hold embryos over for subsequent transfer in a later frozen embryo transfer (FET) cycle (i.e. Staggered IVF) in cases where:
      1.Additional time is needed to perform preimplantation Genetic testing for embryo competency.
      2.In cases where ovarian hyperstimulation increases the risk of life-endangering complications associated with critically severe ovarian hyperstimulation syndrome (OHSS).
      3.To bank (stockpile) embryos for selective transfer of karyotypically normal embryos in older women or those who are diminished ovarian reserve
      4.The ability to store embryos in cases of IVF with third party parenting (Egg Donation; Gestational Surrogacy and Embryo donation) and so improve convenience for those couples seeking such services.
      Preimplantation Genetic Sampling with FET:
      The introduction of preimplantation genetic sampling (PGS) to karyotyping of embryos for selective transfer of the most “competent” embryos, requires in most cases that the tested blastocysts be vitribanked while awaiting test results and then transferred to the uterus at a later date. Many IVF programs have advocated the routine use of PGS in IVF purported to improve IVF outcome. But PGS should in my opinion should only be used selectively. I do not believe that it is needed for all women undergoing IVF. First there is the significant additional cost involved and second it will not benefit everyone undergoing IVF, in my opinion.
      While PGS is a good approach for older women and those with diminished ovarian reserve (DOR) and also for woman who experience recurrent pregnancy loss (RPL) or “unexplained” recurrent IVF failure recent data suggests that it will not improve IVF success rates in women under 36Y who have normal ovarian reserve, who represent the majority of women seeking IVF treatment. Nor is it needed in women (regardless of their age) undergoing IVF with eggs donated by a younger donor. This is because in such women about 1:2/3 of their eggs/embryos are usually chromosomally normal, and in most cases will upon fertilization produce multiple blastocysts per IVF attempt, anyway. Thus in such cases the transfer of 2 blastocysts will likely yield the same outcome regardless of whether the embryos had been subjected to PGS or not. The routine use of
      It is another matter when it comes to women who have diminished ovarian reserve and/or DOR contemplating embryo banking and for women with unexplained recurrent IVF failure, recurrent pregnancy loss and women with alloimmune implantation dysfunction who regardless of their age or ovarian reserve require PGS for diagnostic reasons.
      Embryo Banking: Some IVF centers are doing embryo banking cycles with Preimplantation Genetic Screening (PGS). With Embryo Banking” several IVF cycles are performed sequentially (usually about 2 months apart), up to the egg retrieval stage. The eggs are fertilized and the resulting advanced embryos are biopsied. The biopsy specimens are held over until enough 4-8 blastocysts have been vitribanked, thus providing a reasonable likelihood that one or more will turn out to be PGS-normal. At this point the biopsy specimens (derived all banking cycles) are sent for PGS testing at one time (a significant cost-saver), the chromosomally normal blastocysts are identified and the women are scheduled for timed FET procedures….. with a good prospect of a markedly improved chance of success as well as a reduced risk of miscarriage.

      Hope that helps!

      Geoff Sher

  3. Hi Dr Sher,

    I’m having a FET next month & I just want your opinion on a few things. I’m 29yo & been diagnosed with unexplained fertility. I’ve had four chemical pregnancies over the last two years (all through FET) & two of these were with PGS normal blasts.

    I will be using up my last normal embryo in upcoming cycle. I’ve been put on the ‘Colorado’ protocol but using demaxthesone instead of Prednisone this time & starting from cycle day 1. I’m also taking metformin to control my PCOS.

    It seems to me that my case is of implantation failure & I wonder if substituting the progesterone support from Crinone Gel to Gestone PIO would be of any benefit? Is there anything else you could suggest I talk to my specialist about to increase my chances of success? I’ve also done a laparoscopy recently with endo scratch, dye test & ovarian drilling. Everything was normal except my right ovary was a bit enlarged which I was told is normal for PCOS.

    Many thanks,
    Hana

    • Also wanted to ask where a ERA test would be beneficial? My protocol is always a manufactured one with progynova pills from Day 1.

    • It sounds right to me. However, I would stick with PIO rather than oral or vaginal progesterone. If you feel determined to rather use vaginal progesterone then I would recommend Crinone 8%…twice daily. But not oral!

      Geoff Sher

  4. Hi Dr. Sher, I am 42 years old. I have a 2.5 year old son from my first IVF cycle at 39. We had 4 CCS normal embryos, 3 5AA and 1 5AB. My first transfer resulted in my son. The second transfer failed. Third transfer resulted in a chemical pregnancy, and the fourth resulted in a miscarriage at 8 weeks. The clinic did an integrin biopsy and the result came back that I am missing the beta 3 integrin protein. We did another full cycle in August of this year. We retrieved 10 eggs, 2 fertilized and made it to day 5. Neither was CCS normal. We just did another cycle. We retrieved 18 eggs, and 4 fertilized normally. We are currently waiting for day 5. I have three questions for you. (1) What are the chances that of the 4 that fertilized this cycle, we’ll end up with 1 CCS normal? (2) If we end up with a normal embryo, how successful is depot lupron in treating beta 3 integrin deficiency? (3) Since I had a normal pregnancy (but a history of miscarriage) did we just get lucky or does beta 3 intergrin come and go?

    Many thanks in advance.

    • I am not a greater believer in beta-integrin deficiency and I do not use Lupron depot for this issue. I can tell you that older women as well as those who (regardless of age) have diminished ovarian reserve (DOR) tend to produce fewer and less “competent” eggs, the main reason for reduced IVF success in such cases. The compromised outcome is largely due to the fact that such women tend to have increased LH biological activity which often results in excessive LH-induced ovarian testosterone production which in turn can have a deleterious effect on egg/embryo “competency”.
      Certain ovarian stimulation regimes either promote excessive LH production (e.g. short agonist/Lupron- “flare” protocols, clomiphene and Letrozole), augment LH/hCG delivered through additional administration (e.g. high dosage menotropins such as Menopur), or fail to protect against body’s own/self-produced LH (e.g. late antagonist protocols where drugs such as Ganirelix/Cetrotide/Orgalutron that are first administered 6-7 days after ovarian stimulation has commenced).
      I try to avoid using such protocols/regimes (especially) in older women and those with DOR, favoring instead the use of a modified, long pituitary down-regulation protocol (the agonist/antagonist conversion protocol-A/ACP) augmented by adding supplementary human growth hormone (HGH). I further recommend Staggered IVF with embryo banking of PGS (next generation gene sequencing/NGS)-normal blastocysts in such cases. This type of approach will in my opinion, optimize the chance of a viable pregnancy per embryo transfer procedure and provide an opportunity to capitalize on whatever residual ovarian reserve and egg quality still exists, allowing the chance to “make hay while the sun still shines”.
      I strongly recommend that you visit http://www.DrGeoffreySherIVF.com. Then go to my Blog and access the “search bar”. Type in the titles of any/all of the articles listed below, one by one. “Click” and you will immediately be taken to those you select. Please also take the time to post any questions or comments with the full expectation that I will (as always) respond promptly.

      •Controlled Ovarian Stimulation (COS) for IVF: Selecting the ideal protocol
      •IVF: Factors Affecting Egg/Embryo “competency” during Controlled Ovarian Stimulation(COS)
      •The Fundamental Requirements For Achieving Optimal IVF Success
      •Ovarian Stimulation for IVF using GnRH Antagonists: Comparing the Agonist/Antagonist Conversion Protocol.(A/ACP) With the“Conventional” Antagonist Aproach
      •Anti Mullerian Hormone (AMH) Measurement to Assess Ovarian Reserve and Design the Optimal Protocol for Controlled Ovarian Stimulation (COS) in IVF.
      •The “Biological Clock” and how it should Influence the Selection and Design of Ovarian Stimulation Protocols for IVF.
      •Diagnosing and Treating Infertility due to Diminished Ovarian Reserve (DOR)
      •Controlled Ovarian Stimulation (COS) in Older women and Women who have Diminished Ovarian Reserve (DOR): A Rational Basis for Selecting a Stimulation Protocol
      •Human Growth Hormone Administration in IVF: Does it Enhances Egg/Embryo Quality and Outcome?
      •The BCP: Does Launching a Cycle of Controlled Ovarian Stimulation (COS). Coming off the BCP Compromise Response?
      •Staggered IVF: An Excellent Option When. Advancing Age and Diminished Ovarian Reserve (DOR) Reduces IVF Success Rate
      •Embryo Banking/Stockpiling: Slows the “Biological Clock” and offers a Selective Alternative to IVF-Egg Donation.
      •Preimplantation Genetic Testing (PGS) in IVF: It Should be Used Selectively and NOT be Routine.
      •Preimplantation Genetic Sampling (PGS) Using: Next Generation Gene Sequencing (NGS): Method of Choice.
      •PGS in IVF: Are Some Chromosomally abnormal Embryos Capable of Resulting in Normal Babies and Being Wrongly Discarded?
      •PGS and Assessment of Egg/Embryo “competency”: How Method, Timing and Methodology Could Affect Reliability
      •Implications of “Empty Follicle Syndrome and “Premature Luteinization”
      •Premature Luteinization (“the premature LH surge): Why it happens and how it can be prevented.

      Please call or email Julie Dahan, my patient concierge. She will guide you on how to set up an in-person or Skype consultation with me. You can reach Julie at on her cell phone or via email at any time:
      Julie Dahan
      •Email: Julied@sherivf.com
      •Phone: 702-533-2691
      ?800-780-7437

      Geoff Sher

      I also suggest that you access the 4th edition of my book ,”In Vitro Fertilization, the ART of Making Babies”. It is available as a down-load through http://www.Amazon.com or from most bookstores and public libraries.
      Geoff Sher

  5. Hi Dr. Sher,
    So last week when I had beta test done at 14 days post IUI my level was 28. Today which is 1 week later my beta hcg came back 144.4. They want me to test again in a week but when I asked the nurse how concerned I should be about the slow rise she didn’t really answer me. All she said was let’s wait until next week. Can you please explain to me how I should interpret the results and how worried I should be about miscarriage or ectopic pregnancy? All I’m getting in vague responses.

    Thank you!

    • Unfortunately there is no alternative but to repeat the the beta hCG. I would do so 2 days after the last one and hope that it will double. If it does, then wait 10 days for a confirmatory ultrasound.

      Geoff Sher